Please login to the form below

Not currently logged in
Email:
Password:

type 2 diabetes

This page shows the latest type 2 diabetes news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

AZ hopes improved Bydureon can retain market share. AstraZeneca has gained approval for a new improved formulation of its once-weekly diabetes treatment Bydureon, aimed at maintaining a share in a ... The drug suffered a major setback last year when it

Latest news

  • Novo’s oral diabetes drug hits the mark again Novo’s oral diabetes drug hits the mark again

    The 26-week phase IIIa trial, also known as PIONEER 5, investigated oral semaglutide in 324 patients with type 2 diabetes and who have a kidney-impairment, a serious diabetes complication. ... in people with type 2 diabetes and moderate renal impairment,

  • Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

    Janssen’s type 2 diabetes treatment is in a battle with rival drugs (especialy in its SGLT2 inhibitor class), where proof of cardiovascular benefits are now vital for future market share.

  • Inside the patient-centricity bubble Inside the patient-centricity bubble

    medications. Last year, non-profit Virtua Health was launched, following a successful peer review study, which demonstrated that the group was able to reverse type 2 diabetes in half of its ... medications. “Take diabetes, for example. It’s very hard

  • J&J’s Invokana aces diabetic kidney disease trial, setting up filings J&J’s Invokana aces diabetic kidney disease trial, setting up filings

    The large-scale CREDENCE trial pitted Invokana (canagliflozin) against placebo in type 2 diabetics with established CKD on top of standard therapy. ... Nearly half of all people with type 2 diabetes will develop chronic kidney disease, which means 160m

  • The year of the blockbuster The year of the blockbuster

    The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Despite competing in the crowded type 2 diabetes market, Ozempic

More from news
Approximately 29 fully matching, plus 469 partially matching documents found.

Latest Intelligence

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    Worldwide, there are 352 million at risk of developing type 2 diabetes. ... the market will create extra options for healthcare professionals and, in turn, lead to more people being treated, and treated better, for their diabetes.

  • Speech therapy Speech therapy

    The second looked at weight-loss coaching app Lark and showed that - if delivered properly - a chatbot style intervention could successfully support people at risk of type 2 diabetes both in

  • Positive disruption in business intelligence Positive disruption in business intelligence

    In an analysis of 47, 000 UK HCP posts about type 2 diabetes, 58% of mentions of named drugs were about drug trial data. ... While some high-profile clinical trials were mentioned by name during congress meetings, HCP mentions of drug trials in type 2

  • Managing medication non-adherence Managing medication non-adherence

    By targeting members who are likely to present with type 2 diabetes and other lifestyle-induced chronic illnesses if preventative action is not put in place, these plans have generated successful ... One Drop, the digital diabetes mHealth app, has

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia - would generate cost-savings in excess of £500m a year. ... type 2 diabetes, the latter was associated with significantly greater

More from intelligence
Approximately 5 fully matching, plus 32 partially matching documents found.

Latest appointments

  • Roche’s Torsten Hoffmann to join Zealand Pharma Roche’s Torsten Hoffmann to join Zealand Pharma

    In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity. ... Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it

  • bmore creative hires Kush Rach as new business director bmore creative hires Kush Rach as new business director

    He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2 ... diabetes. Ben Blackmore, bmore creative's MD, told The Directory: "We are

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Evaluating the potential of a pre-launch prodct in a real-life setting

    Our client was developing a new product for treating Type 2 diabetes, which they were preparing for launch. ... In an increasingly competitive diabetes market, with new brands and formulations frequently becoming available, our client needed to determine

  • New insights into making behavioural change work

    Lifestyle conditions, or noncommunicable diseases (NCDs), include obesity, type 2 diabetes mellitus, cardiovascular disease and atherosclerosis [1]. ... References. 1. World Health Organization. Noncommunicable diseases (fact sheet 355). Available at: .

  • Getting personal with wearable tech

    In partnership with Diabetes UK and Hewlett Packard it is deploying mobile health self-management tools (wearable sensors and software) for people with Type 1 and Type 2 diabetes to

  • Dissecting adherence to personalise patient support

    Tailoring the approach to each distinct type. Distinguishing between the two types of non-adherence can better inform patient compliance efforts and clinical practice. ... IMS Institute for Healthcare Informatics (2016). Improving Type 2 Diabetes Therapy

  • Love Your Heart: An Innovative Interactive Video Programme

    Dr. John commented: “The increased risk of CVD for RA sufferers has the same level of severity as those who suffer with type 2 diabetes. ... calculate a QRISK® 2 score (a GP recognised prediction algorithm for CVD).

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics